A
Price
$119.16
Change
-$0.27 (-0.23%)
Updated
Jun 27, 04:59 PM (EDT)
Capitalization
42.66B
52 days until earnings call
CDNA
Price
$19.22
Change
-$0.07 (-0.36%)
Updated
Jun 27, 04:59 PM (EDT)
Capitalization
548.33M
46 days until earnings call
Interact to see
Advertisement

A vs CDNA

Header iconA vs CDNA Comparison
Open Charts A vs CDNABanner chart's image
Agilent Technologies
Price$119.16
Change-$0.27 (-0.23%)
Volume$11.43K
Capitalization42.66B
CareDx
Price$19.22
Change-$0.07 (-0.36%)
Volume$46.64K
Capitalization548.33M
A vs CDNA Comparison Chart in %
Loading...
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
A vs. CDNA commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Buy and CDNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (A: $119.17 vs. CDNA: $19.22)
Brand notoriety: A and CDNA are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: A: 83% vs. CDNA: 127%
Market capitalization -- A: $42.66B vs. CDNA: $548.33M
A [@Medical Specialties] is valued at $42.66B. CDNA’s [@Medical Specialties] market capitalization is $548.33M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

A’s FA Score shows that 1 FA rating(s) are green whileCDNA’s FA Score has 0 green FA rating(s).

  • A’s FA Score: 1 green, 4 red.
  • CDNA’s FA Score: 0 green, 5 red.
According to our system of comparison, A is a better buy in the long-term than CDNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

A’s TA Score shows that 6 TA indicator(s) are bullish while CDNA’s TA Score has 4 bullish TA indicator(s).

  • A’s TA Score: 6 bullish, 4 bearish.
  • CDNA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, A is a better buy in the short-term than CDNA.

Price Growth

A (@Medical Specialties) experienced а +3.12% price change this week, while CDNA (@Medical Specialties) price change was +0.95% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.08%. For the same industry, the average monthly price growth was +1.35%, and the average quarterly price growth was -0.23%.

Reported Earning Dates

A is expected to report earnings on Aug 19, 2025.

CDNA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Medical Specialties (+1.08% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
A($42.7B) has a higher market cap than CDNA($548M). CDNA YTD gains are higher at: -10.229 vs. A (-11.104). A has higher annual earnings (EBITDA): 1.69B vs. CDNA (-84.92M). CDNA has less debt than A: CDNA (34.2M) vs A (2.56B). A has higher revenues than CDNA: A (6.74B) vs CDNA (280M).
ACDNAA / CDNA
Capitalization42.7B548M7,792%
EBITDA1.69B-84.92M-1,990%
Gain YTD-11.104-10.229109%
P/E Ratio34.82N/A-
Revenue6.74B280M2,405%
Total CashN/A235M-
Total Debt2.56B34.2M7,471%
FUNDAMENTALS RATINGS
A vs CDNA: Fundamental Ratings
A
CDNA
OUTLOOK RATING
1..100
1123
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
95
Overvalued
PROFIT vs RISK RATING
1..100
66100
SMR RATING
1..100
4746
PRICE GROWTH RATING
1..100
5647
P/E GROWTH RATING
1..100
6281
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

A's Valuation (20) in the Biotechnology industry is significantly better than the same rating for CDNA (95) in the Medical Specialties industry. This means that A’s stock grew significantly faster than CDNA’s over the last 12 months.

A's Profit vs Risk Rating (66) in the Biotechnology industry is somewhat better than the same rating for CDNA (100) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than CDNA’s over the last 12 months.

CDNA's SMR Rating (46) in the Medical Specialties industry is in the same range as A (47) in the Biotechnology industry. This means that CDNA’s stock grew similarly to A’s over the last 12 months.

CDNA's Price Growth Rating (47) in the Medical Specialties industry is in the same range as A (56) in the Biotechnology industry. This means that CDNA’s stock grew similarly to A’s over the last 12 months.

A's P/E Growth Rating (62) in the Biotechnology industry is in the same range as CDNA (81) in the Medical Specialties industry. This means that A’s stock grew similarly to CDNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACDNA
RSI
ODDS (%)
Bearish Trend 1 day ago
54%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
55%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 1 day ago
62%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
61%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
61%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
60%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
56%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
61%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GRZZX5.27N/A
N/A
Leuthold Grizzly Short Fund
FFTMX21.52N/A
N/A
Fidelity Advisor Asset Manager 50% M
CGTRX9.19N/A
N/A
Columbia Select Large Cap Growth Inst2
OSCCX20.02N/A
N/A
Invesco Main Street Small Cap C
BKRDX8.32N/A
N/A
iShares Developed Real Estate Idx K

CDNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDNA
1D Price
Change %
CDNA100%
-0.36%
VCYT - CDNA
45%
Loosely correlated
+2.13%
ILMN - CDNA
44%
Loosely correlated
+0.67%
NTRA - CDNA
44%
Loosely correlated
-0.12%
A - CDNA
39%
Loosely correlated
-0.21%
GKOS - CDNA
39%
Loosely correlated
+0.36%
More